Document Type
Article
Publication Date
8-29-2022
Abstract
INTRODUCTION: Abiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of adverse effects. Common toxicities vary amongst the two drugs and may have differential interactions with patient co-morbidities, but these patterns are unclear as co-morbidities typically serve as exclusion criteria in clinical trials. Hence, there is no existing guidance on how clinicians may tailor treatment based on patient-specific factors. Analysis of differential patient outcomes between these two drugs can inform future systematic reviews, new clinical studies, and clinical decision making.
METHOD AND ANALYSIS: The framework for this methodology was informed by the Joanna Briggs Institute methodology for scoping reviews. Title and abstract screening will be performed by two independent researchers to create an initial study inventory. This will be followed by full-text screening for study inclusion. Population-based studies describing patient outcomes, common toxicities, and associations with patient co-morbidities following abiraterone or enzalutamide therapy will be included. After data is extracted, it will be summarized for presentation.
ETHICS AND DISSEMINATION: The findings of this scoping review will be published in a peer-reviewed journal. The results will be used to inform future studies on patient-specific factors informing treatment choice between abiraterone and enzalutamide for castration-resistant prostate cancer. All data are from published openly accessible sources, and therefore, no ethical clearance is necessary. The protocol is also registered at https://doi.org/10.6084/m9.figshare.19149227.
Recommended Citation
Shah, Yash B; Shaver, Amy L; Kelly, William Kevin; and Lu-Yao, Grace, "A Scoping Review Protocol to Elucidate Outcomes Following Abiraterone Versus Enzalutamide for Prostate Cancer" (2022). Department of Medical Oncology Faculty Papers. Paper 202.
https://jdc.jefferson.edu/medoncfp/202
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Inclusion Assessment Form.docx (16 kB)
Extraction charting Form.docx (13 kB)
PubMed ID
36037225
Language
English
Comments
This article is the author's final published version in PloS one, Volume 17, Issue 8, August 2022, Pages e0273826.
The published version is available at https://doi.org/10.1371/journal.pone.0273826.
Copyright © 2022 Shah et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.